SynOx Therapeutics
Dublin
About SynOx Therapeutics
SynOx Therapeutics focuses on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for diffuse tenosynovial giant cell tumors and other conditions. The company is supported by experienced investors with a history in biopharma development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $245.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2024)
- Website: synoxtherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/synox-therapeutics-5588 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.